ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases. At the core of the Company is our unique, proprietary FunctionFIRST™ technology platform that generates and selects therapeutic antibodies based on their activity. This antibody generation engine has enabled ARIUS to grow a pipeline of more than 500 antibody drug candidates and five of ARIUS' six lead products target cancer stem cells. In addition to the antibodies we are developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies.